GSK gets late-stage cancer/RA antibody from Genmab; transferred to Novartis
Less than two weeks after acquiring antibody specialist Domantis, GlaxoSmithKline is again building up its large molecule pipeline by in-licensing exclusive worldwide rights to Danish firm Genmab AS's HuMax-CD20 (ofatumumab) fully human monoclonal antibody plus other anti-CD20 antibodies that Genmab may develop.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com